Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis

Full text
Author(s):
Jesus, Jessica Adriana [1] ; Fragoso da Silva, Thays Nicolli [1] ; Yamamoto, Eduardo Seiji [1] ; G. Lago, Joao Henrique [2] ; Dalastra Laurenti, Marcia [1] ; Passero, Luiz Felipe Domingues [3, 4]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Pathol Infect Dis LIM50, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, SP - Brazil
[2] Fed Univ ABC UFABC, Ctr Nat & Human Sci, Ave Estados 5001, BR-09210580 Santo Andre, SP - Brazil
[3] Sao Paulo State Univ UNESP, Inst Biosci, Praca Infante Dom Henrique S-N, BR-11330900 Sao Vicente, SP - Brazil
[4] Sao Paulo State Univ UNESP, Inst Adv Studies Ocean, Rua Joao Francisco Bensdorp 1178, BR-11350011 Sao Vicente, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: PATHOGENS; v. 9, n. 10 OCT 2020.
Web of Science Citations: 0
Abstract

Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantum-infected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-gamma production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decrease the toxicity associated to the conventional drugs. (AU)

FAPESP's process: 18/24077-6 - Pre-clinical studies of non-invasive treatments in leishmaniasis
Grantee:Luiz Felipe Domingues Passero
Support type: Regular Research Grants
FAPESP's process: 18/07885-1 - Biomolecules from plant species of remnant areas of the Atlantic Forest and Cerrado to treat neglected tropical diseases - chemical and pharmacological aspects
Grantee:João Henrique Ghilardi Lago
Support type: BIOTA-FAPESP Program - Regular Research Grants
FAPESP's process: 16/00468-0 - Use of drug repurposing and natural product bioprospection to characterize compounds with in vitro and in vivo leishmanicidal action
Grantee:Luiz Felipe Domingues Passero
Support type: Regular Research Grants
FAPESP's process: 16/10324-6 - Lipid nanoparticles as carriers of triterpenes for the treatment of Experimental Visceral Leishmaniasis
Grantee:Jéssica Adriana de Jesus
Support type: Scholarships in Brazil - Doctorate